Vanflyta: Dosage Form, Projected Sales, NCE-1 Date | Quizartinib

Vanflyta

Vanflyta is an oral medicine used with chemotherapy for adults newly diagnosed with FLT3‑ITD positive acute myeloid leukemia. It continues working as a maintenance therapy to help keep the cancer in check.

The information outlined in the molecule details section below would help you evaluate Para IV filing opportunities early to secure a first-to-file advantage.

Molecule Details :

Molecule Name :

Quizartinib
Innovator :

DAIICHI SANKYO INC
Approval Date :

20-Jul-23
NCE-1 Date :

20-Jul-27
NCE Date :

20-Jul-28
Dosage Form :

Tablet
Strength :

17.7mg and 26.5 mg base
Therapeutic Category :

Anticancer
Revenue ($M) :

30

Year-wise Projected Sales ($M) :

2025 :

55
2026 :

73
2027 :

95
2028 :

118
2029 :

132
2030 :

148
2031 :

158

Looking for this molecule for your next clinical research? Access regulatory-compliant comparators with assured timelines—delivered reliably through our global network.

Why Partner With Us

Supported 1000+ clinical trials globally
Provides services across regulatory, legal & clinical research
Unmatched intelligence on batches, expiry, spacing, and historical data from innovators
Integrated CRO services as part of our offerings
Insights on global pricing for smarter clinical trial supply decisions
Global sourcing capability across US, EU, South Africa, Canada, Japan, Australia, New Zealand, Southeast Asia, and other key markets

Vanflyta

Molecule Details :

Year-wise Projected Sales ($M) :

Looking for this molecule for your next clinical research? Access regulatory-compliant comparators with assured timelines—delivered reliably through our global network.

Why Partner With Us

Login With

Are you sure want to logout from NCE Grid?